A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Study sponsor: Tonix Pharmaceuticals, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-11-01Actual
Enrollment · participants514Actual
Source updated2023-12-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.